Lip, Oral Cavity and Pharynx, Phase III
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Dostarlimab as Sequential Therapy After Chemoradiation in Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
Volunteers
Health Professionals
What is the purpose of this trial?
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with HNSCC (Head and Neck Squamous Cell Carcinoma)
- Trial withGlaxoSmithKline, LLC
- Ages18 years and older
- GenderBoth
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Aarti Bhatia, MD, MPH
- Anca Bulgaru, MD
- Andrea Brennan
- Armand Russo, MD
- Benjamin Newton, MD
- Clarice Grens
- Harold Tara Jr, MD
- Jason Haldas, MD
- Lynn Mastrianni
- Lynsey Teulings
- Matthew Austin, MD
- Michael Chiorazzi, PhD, MD
- Michelle Laspino
- Neal Fischbach, MD
- Renee Moye
- Robert Legare, MD
- Stephen Lattanzi, MD
- Vanna Dest
- Yifei Zhang, MD
- Last Updated12/13/2024
- Study HIC#2000037152